Oncology Drugs

Clear Health's Isoclear offers the power of isotretinoin without oral Accutane's strict rules, but its non-FDA-approved status raises critical questions.

A key regulatory win in Abu Dhabi opens a new international front for NeOnc's war on brain tumors, backed by novel science and significant insider buying.

Laprophan's acquisition of Rivopharm is more than a deal; it's a strategic blueprint for emerging market players aiming for the global pharmaceutical stage.

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

Verastem Oncology's combo therapy posts impressive early data in a notoriously deadly cancer, revealing a shrewd strategy for tackling drug resistance.

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

21 doctors from one practice in a "Top Doctors" Hall of Fame is a headline. But what does it reveal about building trust and innovation in cancer care?

Azitra is betting its future on a radical pivot, leveraging its science for cosmetics and biotech tools. Is this a savvy move for faster cash or a risky dilution of focus?

A new survey reveals the deep toll of canine skin allergies on pets and owners, exposing a massive unmet need that has pharmaceutical giants racing for a cure.

A new collaboration aims to weaponize the immune system against tough GI cancers. We break down the science, strategy, and nearly $800M per program deal.

A new AU$481M deal with Everest Medicines brings a promising FSGS drug closer to 1M Asian patients, part of a larger, de-risked global strategy.

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.

Skin Analytics' DERM Zero is the first AI to get Class III certification for autonomous skin cancer checks on a smartphone, promising to transform access.

Biotech firm Azitra is leveraging its engineered microbe tech to tackle rare diseases and enter the $71B cosmeceutical market. Is this a brilliant pivot or a risky bet?

A landmark court ruling forces a recall of Siemens' latest mammography tech, handing Hologic a major victory and sending shockwaves through Europe's MedTech.

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?

Medincell's latest results show a planned loss but reveal a strategic shift to recurring royalties, fueled by UZEDY®'s success and a pipeline set for growth.

With a novel non-hallucinogenic drug, Enveric Biosciences heads to the BIO convention seeking partners. Can its unique science secure its future?

The PD-L1 biomarker testing market is set to double by 2036, fueling a revolution in cancer care. But as innovation races ahead, who gets left behind?